Armour Residential REIT (ARR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CYBR's subscription ARR surges 65% to $1.03B, fueled by platform cross-selling and larger multi-solution deals.
Shares in Celebrus Technologies PLC (AIM:D4T4, OTC:DFORF) rose 12% after the data software group announced two significant contract wins, adding $1.1 million to its annual recurring revenue and pushing total ARR close to $20 million. The first contract, a three-year deal with a European bank undergoing a digital overhaul, will see the Celebrus Cloud platform used to power hyper-personalised customer experiences.
I remain Buy-rated on Extreme Networks, as its cloud-first, subscription-led transformation is delivering ARR growth, improved margins, and strong free cash flow. Despite some SaaS growth deceleration and margin pressure from product mix, the long-term drivers and strategic partnerships remain intact and compelling. Key watchpoints are ARR reacceleration, Platform ONE's enterprise traction, and maintaining gross margins above 61% as the business scales.
NBIS posts 385% Q1 revenue growth, eyes up to $1B ARR for 2025 as AI demand surges and global expansion accelerates.
ARR, BICP and FNF have been added to the Zacks Rank #5 (Strong Sell) List on June 11, 2025.
CYBR's $1.22 billion ARR, strong subscription gains, and Secure AI Agent debut fuel its identity security momentum.
Despite unpredictable interest rates, ARR.PR.C offers a compelling yield advantage over Treasuries, currently yielding 8.56%, about 400bp above the 10Y Treasury. ARR's strong capital cushion and management's satisfaction with the fixed coupon make a near-term call of ARR.PR.C unlikely, supporting long-term income stability. Our fixed-income strategy, focused on discounted preferred equities like ARR.PR.C continues to outperform long-term bonds, even as rate predictions prove unreliable.
ON24 continues to lose customers, ARR, and revenue, with little evidence of AI-driven innovation or turnaround despite management's claims. ONTF faces intense competition from stronger players like Zoom and struggles to retain recurring revenue, with only half of ARR on multi-year contracts. Profitability is worsening, with negative adjusted EBITDA and ongoing cash burn, making ON24's low valuation a reflection of market distrust.
Downgrading Rapid7 to Hold as near-term demand remains soft and legacy segment weakness persists, despite long-term growth levers and improving execution. Q1 results were mixed: ARR grew 4% year-over-year, but legacy vulnerability management continues to decline, offsetting strong Detection & Response growth. Platform innovation, international expansion, and go-to-market optimization position Rapid7 well for the future, but macro headwinds are delaying meaningful ARR acceleration.
I recommend a hold on ARR due to its attractive dividend yield balanced by risks from interest rate uncertainty and high leverage. Dividend coverage appears adequate short-term, but discrepancies between GAAP and non-GAAP earnings raise long-term sustainability concerns. ARR's financial performance is hindered by high leverage and interest rate sensitivity, limiting growth and increasing risk in current conditions.
Holding a meaningful cash position due to buyouts, providing optionality and safety amidst macro uncertainty, with plans to invest opportunistically. Lifecore Biomedical shows promise with strengthened balance sheet, improved sales force, and potential sale within 3 years, offering significant upside. NextNav's GPS technology investment faces short-term stock weakness but has positive FCC developments and strategic refinancing, indicating long-term potential.